MedTrace Logo

tDCS-Augmented Exposure Therapy for Pathological Fear

NCT03095482 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-12-08

No results posted yet for this study

Summary

This double-blind randomized controlled clinical trial aims to test whether transcranial direct current stimulation (tDCS) can be used to modulate fear extinction learning during exposure therapy for pathological fear, including fear of spiders, snakes, or germs / contamination. Participation takes place over three laboratory visits, including (1) a pre-treatment visit, (2) a treatment and post-treatment visit, and (3) a 1 month follow-up visit. During treatment, participants will receive either 20 minutes of active or sham tDCS, followed by 30 minutes of in vivo exposure therapy.

Conditions

  • Specific Phobias

Interventions

DEVICE

Transcranial Direct Current Stimulation (tDCS)

Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.

BEHAVIORAL

In vivo exposure therapy

Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS

Sponsors & Collaborators

  • University of Texas at Austin

    lead OTHER

Principal Investigators

  • Adam R. Cobb, Ph.D. · The University of Texas at Austin

  • Michael J. Telch, PhD · The University of Texas at Austin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2018-09-06
Completion
2018-09-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03095482 on ClinicalTrials.gov